Correlation analysis on total lymphocyte count and CD4 count of HIV-infected patients

International Journal of Clinical Practice

Volumn 62, Issue 6, 2008, Pages 955-960

  Liu, F R ^a   Guo, F ^b   Ye, J J ^c   Xiong, C F ^c   Zhou, P L ^b   Yin, J G ^b   Ye, L X ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Center for Disease Control of Suizhou City   (China)

^c Hubei Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ROC CURVE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; ROC CURVE;

EID: 43749123486     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01467.x     Document Type: Article

References (26)

1. Fa Post X, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. QJM 1996 89 : 505 8.
2. Stebbing J, Sawleshwarkar S, Michailidis C et al. Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgrad Med J 2005 81 : 586 8.
3. Kamya MR, Semitala FC, Quinn TC et al. Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. Afr Health Sci 2004 4 : 94 101.
4. World Health Organization. Scaling up antiretroviral therapy in resource limited settings : guidelines for a public health approach. Geneva: WHO 2002 Available at http://www.who.int/hiv/topics/arv/ISBN9241545674.pdf BD. The pathobiology of HIV infection. Arch Pathol Lab Med 1990 114 : 235.
5. Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 1999 13 : 565 73.
6. Chaisson RE, Keruly JC, Moore RD. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA 2000 284 : 3128 9.
7. Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002 288 : 222 35.
8. BHIVA. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001 2 : 276 313.
9. Sabin CA, Lampe FC, Chaloner C et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med 2003 4 : 87 93.
10. Rabkin M, El-Sadr W, Katzenstein DA et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 2002 360 : 1503 5.
11. Hirschel B. Antiretroviral treatment and research in resource-poor countries. Lancet 2003 361 : 434 5.
12. Kumarasamy N, Mahajan AP, Flanigan TP et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 2002 31 : 378 83.
13. Erhabor O, Uko EK, Adias T. Absolute lymphocyte count as a marker for CD4 T-lymphocyte count: criterion for initiating antiretroviral therapy in HIV-infected Nigerians. Niger J Med 2006 15 : 56 9.
14. Beck EJ, Kupek EJ, Gompels MM, Pinching AJ. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS 1996 7 : 422 8.
15. Florence E, Dreezen C, Schrooten W et al. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. Int J STD AIDS 2004 15 : 538 42.
16. Anastos K, Shi Q, Audrey L et al. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictor of death and AIDS illness in HIV-1 infected women receiving highly active antiretroviral therapy. J Acquir Immuno Defic Syndr 2004 35 : 383 92.
17. Lava EK, Kutson N, Connie C et al. Total lymphocyte counts in adult HIV/AIDS patients in Port Moresby General Hospital. P N G Med J 2004 47 : 31 8.
18. Lau B, Gange SJ, Phair JP et al. Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men. AIDS 2003 17 : 2035 44.
19. Akanmu AS, Akinsete I, Eshofonie AO et al. Absolute lymphocyte count as surrogate for CD4+ cell count in monitoring response to antiretroviral therapy. Niger postgrad Med J 2001 8 : 105 11.
20. van der Ryst E, Kotze M, Joubert G et al. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1 - infected South African patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998 19 : 238 44.
21. Akinola NO, Olasode O, Adediran IA et al. The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting. Clin Infect Dis 2004 39 : 579 81.
22. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS 2003 17 : 541 5.
23. Flanigan TP, Mahajan A, Kumarasamy N, et al. Total lymphocyte count (TLC) as a surrogate for CD4 count to initiate and monitor HAART in resource-limited countries. In : Conf Retroviruses Opportunistic Infect. 2002 : abstract no. 456-W.
24. Mayer KH. Clinical use of total lymphocyte count for monitoring response to antiretroviral therapy. Infect Dis 2004 38 : 257 62.
25. Schreibman T, Friedland G. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis 2004 32 : 257 62.
26. Lederman MM, Connick E, Landay A et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178 : 70 9.